Allogeneic transplantation for lymphoma: long-term outcome

Area of Science:

• Hematology
• Oncology
• Transplantation Medicine

Background:

• Allogeneic stem cell transplantation (alloSCT) has become a more common treatment for lymphoma patients over the past two decades.
• This trend is driven by the adoption of reduced-intensity and nonmyeloablative conditioning regimens.

Purpose of the Study:

• To review the significant long-term outcomes of lymphoma patients who have undergone alloSCT.
• To synthesize findings from both prospective studies and retrospective analyses.

Main Methods:

• Comprehensive review of existing literature.
• Analysis of prospective and retrospective studies on allografted lymphoma patients.

Main Results:

• AlloSCT can achieve cure rates of 40-60% in aggressive B-cell lymphomas, though outcomes are poorer with chemorefractory or active disease at transplantation.
• Indolent lymphomas show the best prognosis; reduced-intensity alloSCT is recommended for patients relapsing after autologous SCT or with chemorefractory disease.
• Recent data for Hodgkin's lymphoma and T-cell lymphoma are also promising.

Conclusions:

• Despite reduced nonrelapse mortality and plateauing survival curves, disease relapse and long-term morbidity/mortality remain significant concerns.
• Treatment decisions should be individualized based on lymphoma subtype, chemosensitivity, disease status, and patient comorbidities.
• Increased enrollment in multicenter prospective clinical trials is crucial to address remaining questions and improve patient outcomes.